# Trade Mark Journal No.2026/014 3 April 2026

## UK00004355456 16 March 2026 (42)

SYNTASE

International priority date claimed: 30 September 2025 (United States of America) (99421485)

Class 42
  Gene editing, namely, medical and scientific research for the treatment of genetic diseases and disorders in the field of in vivo gene editing therapy; gene editing, namely, pharmaceutical research and development in the field of in vivo gene editing therapy; Research in the field of gene editing technology; Providing a gene editing platform for others to conduct pharmaceutical research and development in the field of in vivo gene editing therapy.

CRISPR Therapeutics AG

Representative: HGF Limited